shhshhh
2021-12-21
nice
Moderna says booster dose of its COVID-19 vaccine appears protective vs Omicron
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
3
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":693287286,"tweetId":"693287286","gmtCreate":1640041257452,"gmtModify":1640041257678,"author":{"id":3570447353222216,"idStr":"3570447353222216","authorId":3570447353222216,"authorIdStr":"3570447353222216","name":"shhshhh","avatar":"https://static.tigerbbs.com/a14aa4a9aad4b805a90b1d67a99f7fef","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":23,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice</p></body></html>","htmlText":"<html><head></head><body><p>nice</p></body></html>","text":"nice","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/693287286","repostId":2192189190,"repostType":4,"repost":{"id":"2192189190","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1640040700,"share":"https://www.laohu8.com/m/news/2192189190?lang=&edition=full","pubTime":"2021-12-21 06:51","market":"us","language":"en","title":"Moderna says booster dose of its COVID-19 vaccine appears protective vs Omicron","url":"https://stock-news.laohu8.com/highlight/detail?id=2192189190","media":"Reuters","summary":"Dec 20 (Reuters) - Moderna Inc said on Monday that a booster dose of its COVID-19 vaccine appeared t","content":"<p>Dec 20 (Reuters) - Moderna Inc said on Monday that a booster dose of its COVID-19 vaccine appeared to be protective against the fast-spreading Omicron variant of the coronavirus in laboratory testing and that the current version of the shot would continue to be its \"first line of defense against Omicron.\"</p>\n<p>The company said its decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently-discovered variant is spreading.</p>\n<p>Moderna said it still plans to develop a vaccine to protect against Omicron specifically and hopes to start clinical trials early next year.</p>\n<p>\"What we have available right now is 1273,\" Dr. Paul Burton, Moderna's chief medical officer, said in an interview. \"It's highly effective, and it's extremely safe. I think it will protect people through the coming holiday period and through these winter months, when we're going to see the most severe pressure of Omicron.\"</p>\n<p>Moderna's shares fell more than 6% at $276.38 on Monday.</p>\n<p>The company said a two-dose course of its vaccine generated low neutralizing antibodies against the Omicron variant, but a 50-microgram booster dose increased neutralizing antibodies against the variant 37 fold. A 100-microgram booster - the same strength as the original shots - drove neutralizing antibodies to more than 80 times pre-boost levels.</p>\n<p>Moderna President Stephen Hoge on a conference call said the company currently does not plan to pursue approval for the higher booster dose.</p>\n<p>The antibody levels generated by the lower dose shot \"are comfortably above\" what would signify a risk of breakthrough infections for other variants of concern, Hoge said.</p>\n<p>Moderna did not specify whether it believes its two-dose regimen will reduce hospitalizations or deaths from the Omicron variant. Studies by other researchers have shown a \"reasonable and robust\" T cell response is maintained against the variant, Hoge said, which could suggest protection against severe disease. T cells in the immune system recognize and eliminate virus-infected cells.</p>\n<p>The new data, which has not yet been peer reviewed, tested blood from people who had received Moderna's vaccine against a pseudovirus engineered to resemble the Omicron variant. It is similar to data discussed last week by top U.S. infectious disease expert Dr. Anthony Fauci.</p>\n<p>It may not be necessary to push antibody levels higher than those generated by the 50-microgram dose for many people, said Hoge. Governments could, however, choose a higher-dose version if they want to confer an enhanced level of protection.</p>\n<p>The company said the 100-microgram dose was generally safe and well tolerated, although there was a trend toward slightly more frequent adverse reactions.</p>\n<p>U.S. regulators authorized the 50-microgram booster of Moderna's vaccine in October.</p>\n<p>Both the Moderna and the Pfizer/BioNTech vaccines have been linked to rare cases of heart inflammation, particularly in young men. Several studies have suggested that Moderna's vaccine is likely to cause the heart inflammation at a higher rate than Pfizer's.</p>\n<p>Omicron, a highly contagious variant first detected last month in southern Africa and Hong Kong, has raced around the globe and been reported in 89 countries, the World Health Organization said on Saturday.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna says booster dose of its COVID-19 vaccine appears protective vs Omicron</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna says booster dose of its COVID-19 vaccine appears protective vs Omicron\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-12-21 06:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dec 20 (Reuters) - Moderna Inc said on Monday that a booster dose of its COVID-19 vaccine appeared to be protective against the fast-spreading Omicron variant of the coronavirus in laboratory testing and that the current version of the shot would continue to be its \"first line of defense against Omicron.\"</p>\n<p>The company said its decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently-discovered variant is spreading.</p>\n<p>Moderna said it still plans to develop a vaccine to protect against Omicron specifically and hopes to start clinical trials early next year.</p>\n<p>\"What we have available right now is 1273,\" Dr. Paul Burton, Moderna's chief medical officer, said in an interview. \"It's highly effective, and it's extremely safe. I think it will protect people through the coming holiday period and through these winter months, when we're going to see the most severe pressure of Omicron.\"</p>\n<p>Moderna's shares fell more than 6% at $276.38 on Monday.</p>\n<p>The company said a two-dose course of its vaccine generated low neutralizing antibodies against the Omicron variant, but a 50-microgram booster dose increased neutralizing antibodies against the variant 37 fold. A 100-microgram booster - the same strength as the original shots - drove neutralizing antibodies to more than 80 times pre-boost levels.</p>\n<p>Moderna President Stephen Hoge on a conference call said the company currently does not plan to pursue approval for the higher booster dose.</p>\n<p>The antibody levels generated by the lower dose shot \"are comfortably above\" what would signify a risk of breakthrough infections for other variants of concern, Hoge said.</p>\n<p>Moderna did not specify whether it believes its two-dose regimen will reduce hospitalizations or deaths from the Omicron variant. Studies by other researchers have shown a \"reasonable and robust\" T cell response is maintained against the variant, Hoge said, which could suggest protection against severe disease. T cells in the immune system recognize and eliminate virus-infected cells.</p>\n<p>The new data, which has not yet been peer reviewed, tested blood from people who had received Moderna's vaccine against a pseudovirus engineered to resemble the Omicron variant. It is similar to data discussed last week by top U.S. infectious disease expert Dr. Anthony Fauci.</p>\n<p>It may not be necessary to push antibody levels higher than those generated by the 50-microgram dose for many people, said Hoge. Governments could, however, choose a higher-dose version if they want to confer an enhanced level of protection.</p>\n<p>The company said the 100-microgram dose was generally safe and well tolerated, although there was a trend toward slightly more frequent adverse reactions.</p>\n<p>U.S. regulators authorized the 50-microgram booster of Moderna's vaccine in October.</p>\n<p>Both the Moderna and the Pfizer/BioNTech vaccines have been linked to rare cases of heart inflammation, particularly in young men. Several studies have suggested that Moderna's vaccine is likely to cause the heart inflammation at a higher rate than Pfizer's.</p>\n<p>Omicron, a highly contagious variant first detected last month in southern Africa and Hong Kong, has raced around the globe and been reported in 89 countries, the World Health Organization said on Saturday.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","BK4534":"瑞士信贷持仓","MRNA":"Moderna, Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4139":"生物科技","BK4568":"美国抗疫概念"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2192189190","content_text":"Dec 20 (Reuters) - Moderna Inc said on Monday that a booster dose of its COVID-19 vaccine appeared to be protective against the fast-spreading Omicron variant of the coronavirus in laboratory testing and that the current version of the shot would continue to be its \"first line of defense against Omicron.\"\nThe company said its decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently-discovered variant is spreading.\nModerna said it still plans to develop a vaccine to protect against Omicron specifically and hopes to start clinical trials early next year.\n\"What we have available right now is 1273,\" Dr. Paul Burton, Moderna's chief medical officer, said in an interview. \"It's highly effective, and it's extremely safe. I think it will protect people through the coming holiday period and through these winter months, when we're going to see the most severe pressure of Omicron.\"\nModerna's shares fell more than 6% at $276.38 on Monday.\nThe company said a two-dose course of its vaccine generated low neutralizing antibodies against the Omicron variant, but a 50-microgram booster dose increased neutralizing antibodies against the variant 37 fold. A 100-microgram booster - the same strength as the original shots - drove neutralizing antibodies to more than 80 times pre-boost levels.\nModerna President Stephen Hoge on a conference call said the company currently does not plan to pursue approval for the higher booster dose.\nThe antibody levels generated by the lower dose shot \"are comfortably above\" what would signify a risk of breakthrough infections for other variants of concern, Hoge said.\nModerna did not specify whether it believes its two-dose regimen will reduce hospitalizations or deaths from the Omicron variant. Studies by other researchers have shown a \"reasonable and robust\" T cell response is maintained against the variant, Hoge said, which could suggest protection against severe disease. T cells in the immune system recognize and eliminate virus-infected cells.\nThe new data, which has not yet been peer reviewed, tested blood from people who had received Moderna's vaccine against a pseudovirus engineered to resemble the Omicron variant. It is similar to data discussed last week by top U.S. infectious disease expert Dr. Anthony Fauci.\nIt may not be necessary to push antibody levels higher than those generated by the 50-microgram dose for many people, said Hoge. Governments could, however, choose a higher-dose version if they want to confer an enhanced level of protection.\nThe company said the 100-microgram dose was generally safe and well tolerated, although there was a trend toward slightly more frequent adverse reactions.\nU.S. regulators authorized the 50-microgram booster of Moderna's vaccine in October.\nBoth the Moderna and the Pfizer/BioNTech vaccines have been linked to rare cases of heart inflammation, particularly in young men. Several studies have suggested that Moderna's vaccine is likely to cause the heart inflammation at a higher rate than Pfizer's.\nOmicron, a highly contagious variant first detected last month in southern Africa and Hong Kong, has raced around the globe and been reported in 89 countries, the World Health Organization said on Saturday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":380,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/693287286"}
精彩评论